عربي
If You Are a Diabetic Patient in Qatar Asking About Ozempic for Weight Loss, Your Cardiologist Has a More Important Reason to Consider It.
GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — have transformed diabetes management. But in 2026, the most clinically significant development is their cardiovascular protection profile.
At American Hospital Clinics Doha, Dr. Sajjad Ali provides comprehensive cardiovascular risk assessment for diabetic patients — including GLP-1 therapy evaluation as part of the overall cardiac management plan.
Why This Matters Specifically for Qatar Patients With Diabetes
Qatar has one of the highest diabetes prevalence rates in the world — estimated at over 16% of the adult population. Cardiovascular disease is the leading cause of death in people with Type 2 diabetes. In 2026, the two cannot be managed in silos.
For a diabetic patient in Qatar with any of the following, GLP-1 therapy now warrants cardiological consideration:
- Existing cardiovascular disease — prior heart attack, stroke, or established arterial disease
- Multiple cardiovascular risk factors — hypertension, high cholesterol, smoking, obesity, family history
- Poor cardiovascular risk control despite current diabetes medications
- HbA1c persistently above target despite optimal lifestyle and metformin
- Heart failure with reduced ejection fraction alongside diabetes
What the Evidence Shows in 2026
1. The SELECT Trial (Semaglutide)
17,604 patients with cardiovascular disease and obesity — semaglutide reduced major adverse cardiovascular events (MACE) by 20% over five years, on top of existing standard-of-care medications.
2. The LEADER and SUSTAIN Trials
Liraglutide and semaglutide both demonstrated cardiovascular risk reduction in patients with Type 2 diabetes and established cardiovascular disease. MACE reduction of 13–26% depending on the trial and population.
3. The SURPASS-CVOT Trial (Tirzepatide)
Results in 2025–2026 are establishing tirzepatide's cardiovascular benefit profile in Type 2 diabetes. The cardiovascular benefit appears at least equivalent to semaglutide.
4. Beyond MACE — Additional Cardiac Benefits
- Blood pressure reduction — consistent across all major GLP-1 trials
- Reduced kidney disease progression — critical for diabetic patients at cardiac risk
- Reduced inflammation (CRP) — direct arterial anti-inflammatory effect
- Heart failure hospitalisation reduction — demonstrated in STEP-HFpEF 2023
Why Choose American Hospital Clinics Doha?
- Comprehensive diabetes and cardiovascular risk assessment in one consultation
- GLP-1 therapy eligibility evaluated within full cardiac context
- HbA1c, lipid panel, kidney function, and ECG available on-site
- Insurance authorisation support where applicable
- Most major Qatar insurance plans accepted
"In 2026, if your patient has diabetes and cardiovascular disease, asking whether they should be on a GLP-1 drug is no longer a diabetes question — it is a cardiology question. The evidence for cardiac benefit is now strong enough that this conversation should happen at every cardiology appointment for eligible diabetic patients in Qatar." — Dr. Sajjad Ali, Cardiology, AHC Doha
